Last reviewed · How we verify
CBP501 and Cisplatin
At a glance
| Generic name | CBP501 and Cisplatin |
|---|---|
| Also known as | CBP501 and CDDP |
| Sponsor | CanBas Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (PHASE2)
- Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) (PHASE1, PHASE2)
- CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (PHASE1)
- Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) (PHASE2)
- Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBP501 and Cisplatin CI brief — competitive landscape report
- CBP501 and Cisplatin updates RSS · CI watch RSS
- CanBas Co. Ltd. portfolio CI